Management of Hypersplenism

Understanding Hypersplenism

• Hypersplenism is common in patients with advanced cirrhosis and portal hypertension, affecting all hematological cell lines, with thrombocytopenia being the most common manifestation 1, 2
• The etiology is multifactorial, including portal hypertension with intra-splenic sequestration, myeloid toxicity, anti-platelet antibodies, and/or low levels of thrombopoietin 2
• A low platelet count should be evaluated within the broader context of cirrhosis affecting hemostasis, as it alone does not necessarily predict bleeding risk in cirrhotic patients 2

Diagnostic Approach

• Rotational thromboelastometry may be superior to routine coagulation laboratory tests for accurately predicting bleeding risk during high-risk procedures, including liver transplantation 2
• In cases of splenic vein thrombosis, diagnostic procedures should include computed tomography scan, hepatic ultrasonography, angiography, and bone marrow biopsy 3
• JAK2V617F mutation determination can be helpful diagnostically in cases of Budd-Chiari syndrome and portal vein thrombosis 3

Management Strategies

• The American College of Radiology suggests that partial splenic embolization can effectively reduce hypersplenism by decreasing splenic volume and portal pressure 4
• Thrombopoietin receptor agonists, such as avatrombopag and lusutrombopag, should be considered before high-risk procedures or in the presence of bleeding, as they are superior to no treatment in avoiding platelet transfusion and rescue therapy 2
• Platelet transfusion can work synergistically with local hemostatic means in patients requiring high-risk procedures or with active bleeding 2

Interventional Procedures

• Partial splenic embolization can result in resolution of hemorrhage without recurrence in patients with gastric varices and splenic vein occlusion 5
• When combined with other therapies like transjugular balloon-occluded retrograde transvenous obliteration, partial splenic embolization significantly reduces the risk of esophageal variceal aggravation 4
• Splenic vein recanalization, including transjugular recanalization with angioplasty or stenting, has shown resolution of upper GI bleeding without recurrence 5

Special Considerations

• After liver transplantation, portal pressure decreases rapidly, and thrombopoietin levels increase starting from day 1, with platelet counts usually normalizing within 2 weeks 2
• In patients with pre-transplant splenomegaly, subclinical hypersplenism may persist 2

Hypersplenism Treatment Options

Introduction to Treatment Strategies

• The American College of Radiology recommends portal hypertension treatment with vasoactive drugs (terlipressin, somatostatin, or octreotide) as the primary approach for managing hypersplenism 6
• Endoscopic variceal ligation (EVL) has high efficacy in patients with esophageal variceal bleeding and is often combined with vasoactive drugs 6, 7
• The combination of EVL and partial splenic embolization (PSE) extends variceal eradication and reduces mortality in patients with large esophageal varices, hypersplenism, and thrombocytopenia 6, 7
• Transjugular intrahepatic portosystemic shunt (TIPS) can be used to treat portal hypertension-related hypersplenism, but there is a risk of shunt dysfunction 6, 7
• Surgical shunt procedures are effective in preventing bleeding but have not shown a survival advantage 6
• Congenital portosystemic shunts can cause hypersplenism and may require surgical or laparoscopic ligation or interventional radiology obliteration in symptomatic patients 8

Treatment Algorithms

• The Hepatology society recommends identifying and treating the underlying cause of hypersplenism (portal hypertension, cirrhosis, hematological disorders) 8
• For resistant hypersplenism, partial splenic embolization is the preferred first option, followed by TIPS or surgical shunt 6

Approach to Hypersplenism

Initial Diagnostic Evaluation

• The European Association for the Study of the Liver recommends assessing for underlying cirrhosis with liver function tests, hepatic ultrasound with Doppler, and consider elastography to distinguish cirrhosis from isolated portal vein thrombosis 9
• Consider extrahepatic portal vein obstruction (EHPVO) in patients with features of portal hypertension but minimal liver dysfunction and normal transaminases, as recommended by the European Association for the Study of the Liver 9
• Evaluate for prothrombotic disorders (myeloproliferative neoplasms, antiphospholipid syndrome, inherited thrombophilia) and local factors (pancreatitis, inflammatory bowel disease) that may contribute to portal vein thrombosis, according to the European Association for the Study of the Liver 9

Management of the Underlying Condition

• The American Association for the Study of Liver Diseases notes that gastrointestinal bleeding is the most frequent complication of portal hypertension in EHPVO 9
• Anticoagulation should be considered to prevent thrombotic extension or recurrence in EHPVO, though evidence for benefit/risk ratio requires further evaluation, as stated by the European Association for the Study of the Liver 9
• Portal cholangiopathy may develop from compression of bile ducts by cavernomatous collaterals, requiring surveillance for biliary complications, according to the European Association for the Study of the Liver 9

Management of Cytopenias

• The American Gastroenterological Association recommends avoiding routine prophylactic platelet transfusions or fresh frozen plasma before nonsurgical procedures, as baseline bleeding risk is low and independent of preprocedure prophylaxis 10
• Do not rely solely on platelet count to determine bleeding risk or need for transfusion in cirrhotic patients, as advised by the American Gastroenterological Association 10
• Avoid routine prophylactic blood product transfusions before low-risk procedures, given short half-life, cost, and risk of alloimmunization, according to the American Gastroenterological Association 10

Interventional Options for Refractory Hypersplenism

• The Society of Interventional Radiology notes that combined partial splenic embolization (PSE) and balloon-occluded retrograde transvenous obliteration (BRTO) significantly reduces esophageal variceal aggravation (9% vs 45% at 3 years) 11
• Consider concomitant PSE when performing BRTO to mitigate increased portal hypertension and prevent esophageal variceal worsening, as recommended by the Society of Interventional Radiology 11
• Rifaximin prophylaxis from 2 weeks before non-urgent TIPS through 6 months post-procedure significantly reduces post-TIPS hepatic encephalopathy, according to the European Association for the Study of the Liver 12
• The European Association for the Study of the Liver and the International Liver Transplantation Society state that MELD score >11 predicts poor outcomes with portosystemic shunt embolization; select patients carefully [12] [13]

Management of Hypersplenism in Adults

Treatment Algorithm

• For patients requiring procedures within 10-14 days, the American Society of Hematology recommends starting thrombopoietin receptor agonists 10-14 days before the planned procedure, as they work synergistically with local hemostatic measures during procedures 14
• Partial splenic embolization does not completely compromise splenic immune function, and is the preferred interventional approach for persistent symptomatic hypersplenism, effectively reducing hypersplenism by decreasing splenic volume and portal pressure, with a lower complication rate than splenectomy 14

Special Populations

• For immune thrombocytopenia (ITP) with hypersplenism lasting ≥3 months, corticosteroid-dependent or non-responsive, the American Society of Hematology conditionally recommends considering TPO-RA rather than rituximab, and rituximab rather than splenectomy, and delaying splenectomy for at least 1 year after diagnosis due to potential for spontaneous remission 15

Clinical and Diagnostic Aspects of Hypersplenism

Etiology

• Lymphoproliferative disorders are identified as a cause of secondary hypersplenism, leading to splenomegaly and peripheral cytopenias. 16

Complications

• Hepatic fibrosis can progress to cirrhosis in the setting of hypersplenism, indicating that chronic splenic sequestration may aggravate liver disease. 16

Imaging Findings

• Cross‑sectional imaging (CT or MRI) may demonstrate a markedly enlarged spleen, with splenic volume potentially exceeding ten times the normal size in affected individuals. 16

Laboratory Findings

• Serum transaminase concentrations are often elevated early in the disease course of patients with hypersplenism, reflecting concurrent hepatic injury. 16